These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 27766224)
1. Improvement of Meloxicam Solubility Using a β-Cyclodextrin Complex Prepared via the Kneading Method and Incorporated into an Orally Disintegrating Tablet. Ainurofiq A; Choiri S; Azhari MA; Siagian CR; Suryadi BB; Prihapsara F; Rohmani S Adv Pharm Bull; 2016 Sep; 6(3):399-406. PubMed ID: 27766224 [No Abstract] [Full Text] [Related]
2. Development and optimization of a meloxicam/β-cyclodextrin complex for orally disintegrating tablet using statistical analysis. Ainurofiq A; Choiri S Pharm Dev Technol; 2018 Jun; 23(5):464-475. PubMed ID: 27875913 [TBL] [Abstract][Full Text] [Related]
3. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation. Rahman Z; Siddiqui A; Khan MA Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1300-9. PubMed ID: 23800704 [TBL] [Abstract][Full Text] [Related]
4. Formulation of cyclodextrin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability. Desai S; Poddar A; Sawant K Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():826-34. PubMed ID: 26478377 [TBL] [Abstract][Full Text] [Related]
5. Design, Optimization, and Correlation of In Vitro/In Vivo Disintegration of Novel Fast Orally Disintegrating Tablet of High Dose Metformin Hydrochloride Using Moisture Activated Dry Granulation Process and Quality by Design Approach. H Aodah A; H Fayed M; Alalaiwe A; B Alsulays B; F Aldawsari M; Khafagy ES Pharmaceutics; 2020 Jun; 12(7):. PubMed ID: 32605039 [TBL] [Abstract][Full Text] [Related]
6. Formulation and In-vitro Evaluation of Orally Disintegrating Tablets of Olanzapine-2-Hydroxypropyl-β-Cyclodextrin Inclusion Complex. Ajit Shankarrao K; Dhairysheel Mahadeo G; Pankaj Balavantrao K Iran J Pharm Res; 2010; 9(4):335-47. PubMed ID: 24381598 [TBL] [Abstract][Full Text] [Related]
7. Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions. Dehghani H; Taheri A; Homayouni A Curr Drug Deliv; 2017; 14(5):709-717. PubMed ID: 27142108 [TBL] [Abstract][Full Text] [Related]
8. Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer's disease patients. Liew KB; Tan YT; Peh KK Drug Dev Ind Pharm; 2015 Apr; 41(4):583-93. PubMed ID: 24495273 [TBL] [Abstract][Full Text] [Related]
9. Formulation and characterization of oral rapid disintegrating tablets of levocetirizine. Samvedna S; Jindal S; Mishra G; Madan JR; Gupta G; Awasthi R; Pinto TJA; Dua K; Kulkarni GT Polim Med; 2018; 48(1):31-40. PubMed ID: 30657656 [TBL] [Abstract][Full Text] [Related]
10. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex. Wang L; Zeng F; Zong L Pharm Dev Technol; 2013; 18(5):1101-10. PubMed ID: 22759202 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex. Kim JI; Cho SM; Cui JH; Cao QR; Oh E; Lee BJ Int J Pharm; 2013 Oct; 455(1-2):31-9. PubMed ID: 23933050 [TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation of an orally fast disintegrating tablet formulation containing a hydrophobic drug. Comoglu T; Unal B Pharm Dev Technol; 2015 Jan; 20(1):60-4. PubMed ID: 24295202 [TBL] [Abstract][Full Text] [Related]
13. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. Rahman Z; Zidan AS; Khan MA Int J Pharm; 2010 Nov; 400(1-2):49-58. PubMed ID: 20801200 [TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes. Desai C; Prabhakar B Drug Dev Ind Pharm; 2015; 41(10):1589-607. PubMed ID: 25350555 [TBL] [Abstract][Full Text] [Related]
15. Development of pediatric orally disintegrating mini-tablets containing atomoxetine hydrochloride-β-cyclodextrin inclusion complex using experimental design. Özyılmaz ED; Comoglu T Drug Dev Ind Pharm; 2022 Nov; 48(11):667-681. PubMed ID: 36454038 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics. Lou H; Liu M; Qu W; Hu Z; Brunson E; Johnson J; Almoazen H Drug Dev Ind Pharm; 2014 Jul; 40(7):910-8. PubMed ID: 23621768 [TBL] [Abstract][Full Text] [Related]
17. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying. Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963 [TBL] [Abstract][Full Text] [Related]
18. Expedited Development of Diphenhydramine Orally Disintegrating Tablet through Integrated Crystal and Particle Engineering. Wang C; Hu S; Sun CC Mol Pharm; 2017 Oct; 14(10):3399-3408. PubMed ID: 28825961 [TBL] [Abstract][Full Text] [Related]
19. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies. Shende PK; Gaud RS; Bakal R; Patil D Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091 [TBL] [Abstract][Full Text] [Related]
20. Cyclodextrin inclusion complex of racecadotril: effect of drug-β- cyclodextrin ratio and the method of complexation. Semalty M; Panchpuri M; Singh D; Semalty A Curr Drug Discov Technol; 2014 Jun; 11(2):154-61. PubMed ID: 24188445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]